You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

anti-IGF-1R

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8 Trial

Recruiting
  • Anatomic Stage I Breast Cancer AJCC v8
  • +19 more
  • pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine
  • +3 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Aug 1, 2022

Molecular Imaging Trial in Harbin (68Ga-NODAGA-ZIGF-1R:4:40)

Unknown status
  • Molecular Imaging
  • 68Ga-NODAGA-ZIGF-1R:4：40
  • Harbin, Heilongjiang, China
    TOF-PET/CT/MR center of the Fourth Hospital of Harbin Medical Un
Feb 20, 2020

Role of LncRNA H19 in The Regulation of IGF-1R Expression

Completed
  • Hepatocellular Carcinoma
  • +2 more
  • Blood sample collection
  • Mansoura, Dakahliya, Egypt
  • +1 more
Apr 5, 2022

Rhabdomyosarcoma, Rhabdomyosarcoma, Alveolar, Rhabdomyosarcoma, Embryonal Trial in Los Angeles, Bethesda (Dasatinib, Ganitumab)

Terminated
Has Results
  • Rhabdomyosarcoma
  • +2 more
  • Los Angeles, California
  • +1 more
Mar 17, 2022

IGF1R And p95HER2 as Prognostic Factors in Non Small Cell Lung

Completed
  • Non Small Cell Lung Cancer
  • Protein expression by immunohistochemistry and immunofluorescence
  • Rozzano, Milan, Italy
    Istituto Clinco Humanitas
Sep 8, 2022

Diffuse Large B Cell Lymphoma, Relapse/Recurrence, Extranodal Extension Trial in Beijing (Low-Dose Decitabine plus anti-PD-1)

Recruiting
  • Diffuse Large B Cell Lymphoma
  • +3 more
  • Low-Dose Decitabine plus anti-PD-1
  • Beijing, Beijing, China
    ChinaPLAGH
Apr 18, 2023

Lung Cancer Trial in Hamilton, Ottawa, Toronto (anti-IGF-1R recombinant mAb MK-0646, cisplatin, etoposide)

Completed
  • Lung Cancer
  • anti-IGF-1R recombinant monoclonal antibody MK-0646
  • +2 more
  • Hamilton, Ontario, Canada
  • +2 more
Apr 6, 2020

Acute T-lymphoblastic Leukemia, Acute T-lymphoblastic Lymphoma Trial in Xuzhou (CAR-T Cell Infusion)

Recruiting
  • Acute T-lymphoblastic Leukemia
  • Acute T-lymphoblastic Lymphoma
  • CAR-T Cell Infusion
  • Xuzhou, Jiangsu, China
    The Affiliated Hospital of Xuzhou Medical University
Feb 23, 2023

Thyroid Eye Disease, Graves Orbitopathy, Endocrine System Diseases Trial in Canada, United Kingdom, United States (Linsitinib,

Recruiting
  • Thyroid Eye Disease
  • +11 more
  • Beverly Hills, California
  • +22 more
Jan 30, 2023

Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size, Iris Melanoma Trial in

Completed
Has Results
  • Ciliary Body and Choroid Melanoma, Medium/Large Size
  • +5 more
  • Cixutumumab
  • Laboratory biomarker analysis
  • Philadelphia, Pennsylvania
  • +1 more
Feb 5, 2020

NPC Trial in Guangzhou (Sintilimab, IBI310)

Active, not recruiting
  • NPC
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Oct 3, 2022

Relapsed/Refractory Non-Hodgkin Lymphoma Trial in Duarte, Amsterdam (BMS-986458, Rituximab)

Not yet recruiting
  • Relapsed/Refractory Non-Hodgkin Lymphoma
  • Duarte, California
  • +1 more
Oct 13, 2023

HER2/Neu Negative, No Evidence of Disease, One or More Positive Axillary Nodes Trial in Seattle, Madison (Laboratory Biomarker

Active, not recruiting
  • HER2/Neu Negative
  • +10 more
  • Laboratory Biomarker Analysis
  • +2 more
  • Seattle, Washington
  • +1 more
Jan 11, 2022

Adenocarcinoma, Stomach Tumor, Gastroesophageal-junction Cancer Trial in Shanghai (radiation, biological, drug, procedure)

Recruiting
  • Adenocarcinoma
  • +8 more
  • Radiotherapy targeted to the primary lesion
  • +7 more
  • Shanghai, China
    Fudan University Shanghai Cancer Center
Nov 7, 2023

Thyroid Eye Disease, Graves Orbitopathy, Endocrine System Diseases Trial in Miami, Morgantown (linsitinib)

Recruiting
  • Thyroid Eye Disease
  • +11 more
  • Miami, Florida
  • +1 more
Oct 31, 2023

Diffuse Cutaneous Systemic Sclerosis Trial in United States (TEPEZZA, Placebo)

Recruiting
  • Diffuse Cutaneous Systemic Sclerosis
  • TEPEZZA
  • Placebo
  • Los Angeles, California
  • +6 more
Jul 22, 2022

Anti-obesity Pharmacotherapy and Inflammation

Not yet recruiting
  • Obesity
  • Liraglutide or Semaglutide
  • Phentermine-Topiramate combination
  • New Orleans, Louisiana
  • +1 more
Mar 3, 2023

Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Recurrent Chronic Myelomonocytic Leukemia Trial in Houston

Recruiting
  • Chronic Myelomonocytic Leukemia
  • +5 more
  • Canakinumab
  • Houston, Texas
    M D Anderson Cancer Center
Dec 7, 2022

Metastatic Ewing Sarcoma, Metastatic Malignant Tumor in the Bone, Metastatic Malignant Tumor in the Bone Marrow Trial in Canada,

Active, not recruiting
Has Results
  • Metastatic Ewing Sarcoma
  • +5 more
  • Birmingham, Alabama
  • +316 more
Jan 28, 2023

Body Image, Anti Fat Bias Trial in Bristol (Positive body image TV show, Positive body image music video, Active control TV show

Recruiting
  • Body Image
  • Anti Fat Bias
  • Positive body image TV show
  • +3 more
  • Bristol, United Kingdom
    Centre for Appearance Research, UWE
Nov 21, 2023

Bipolar Disorder (BD), Suicidality Trial in Toronto (Intravenous Ketamine (IV))

Recruiting
  • Bipolar Disorder (BD)
  • Suicidality
  • Intravenous Ketamine (IV)
  • Toronto, Ontario, Canada
    Centre for Addiction and Mental Health
Jul 19, 2022

Multiple Myeloma Trial in Shanghai (Human Derived anti-BCMA CAR-T Injection)

Recruiting
  • Multiple Myeloma
  • Human Derived anti-BCMA CAR-T Injection
  • Shanghai, Shanghai, China
    Shanghai Changzheng Hospital
Mar 27, 2022

DLBCL Trial (Sintilimab, Rituximab)

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma
  • (no location specified)
Mar 6, 2022

Oral Mucositis Trial (Bocaliner, Benzydamine)

Enrolling by invitation
  • Oral Mucositis
  • Yerevan, Armenia
    Hematology Center after Prof. R. Yeolyan
Dec 20, 2022

B-cell Lymphoma Trial in Hangzhou (PD1 specific integrated anti-CD19 Chimeric Antigen Receptor T Cells)

Active, not recruiting
  • B-cell Lymphoma
  • PD1 specific integrated anti-CD19 Chimeric Antigen Receptor T Cells
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital, Zhejiang University School of Med
Sep 28, 2022